Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit
Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit
复制标题
DOI：
10.1101/2020.03.13.20035618
复制
发表时间：
2020-06-01
影响因子：
9.4
通讯作者：
Greninger, Alexander L.
中科院分区：
文献类型：
--
作者：
Nalla, Arun K.;Casto, Amanda M.;Greninger, Alexander L.
自 2019 年 12 月开始，已知全球有近 40 万人感染了严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)。该病毒现已传播到包括美国在内的超过 168 个国家，其中在华盛顿西雅图都市区发现了第一批聚集性病例。鉴于许多地方病例数量迅速增加，提供准确、高通量的 SARS-CoV-2 检测对于应对当前公共卫生危机至关重要。在华盛顿大学临床病毒学实验室（UW Virology Lab）优化 SARS-CoV-2 检测的过程中，我们使用七种不同的引物探针组和一种检测试剂盒评估了检测结果。我们发现最灵敏的测定是使用 Corman 等人描述的 E 基因引物探针组的测定。 （V. M. Corman、O. Landt、M. Kaiser、R. Molenkamp 等人，Euro Surveill 25:2000045, 2020，https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045）和 CDC（病毒疾病司、中心）开发的 N2 集疾病控制和预防，2020 年，https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-per-panel-primer-probes.pdf）。发现所有测试的检测都对 SARS-CoV-2 具有高度特异性，无论使用何种引物探针组或试剂盒，在我们的分析中都没有观察到与其他呼吸道病毒的交叉反应。这些结果将为在全球迫切需要提高检测能力之际积极制定 SARS-CoV-2 检测方案的其他临床实验室提供有价值的信息。
Nearly 400,000 people worldwide are known to have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) beginning in December 2019. The virus has now spread to over 168 countries including the United States, where the first cluster of cases was observed in the Seattle metropolitan area in Washington. Given the rapid increase in the number of cases in many localities, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we evaluated assays using seven different primer-probe sets and one assay kit. We found that the most sensitive assays were those that used the E-gene primerprobe set described by Corman et al. (V. M. Corman, O. Landt, M. Kaiser, R. Molenkamp, et al., Euro Surveill 25:2000045, 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set developed by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/ downloads/rt-per-panel-primer-probes.pdf). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer-probe set or kit used. These results will provide valuable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide.